6-week Safety and PD Study in Adults With NAFLD

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-alcoholic Fatty Liver Disease

In brief

IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE

Key facts

Study ID

NCT03256526

Run by

Pfizer

People needed

53

Starts

2017-09-27

Expected to finish

2018-04-27

Last updated by the study team

2019-04-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI at least 28 kg/m2
• Type 2 diabetes and/or metabolic syndrome

You may not qualify if…

• Liver disease
• Type 1 diabetes
• Recent heart attack or stroke
• Inability to have an MRI scan

Where it is running

• National Research Institute — Los Angeles, California, United States
• Avail Clinical Research, LLC — DeLand, Florida, United States
• Stand-Up MRI of Miami — Miami, Florida, United States
• Avail Clinical Research, LLC — Orange City, Florida, United States
• Qps-Mra, Llc — South Miami, Florida, United States
• Sterling Research Group, Ltd. — Cincinnati, Ohio, United States
• WR-ClinSearch LLC — Chattanooga, Tennessee, United States
• Clinical Trials of Texas, Inc. — San Antonio, Texas, United States
• National Clinical Research, Inc — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.